Rigel Pharma (RIGL) Misses Q4 EPS by 3c

Rigel Pharma (NASDAQ: RIGL) reported Q4 EPS of ($0.21), $0.03 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $2.18 million versus the consensus estimate of $16 million.

"The collaboration with BMS in immuno-oncology provides a pivot point as Rigel focuses on immunology and oncology. In the future, we will be discussing various opportunities within our pipeline in these areas," said Raul Rodriguez, president and chief executive officer of Rigel. "We continue to focus our resources on ensuring the timely execution of our phase 3 clinical studies in ITP, in addition, we are actively pursuing additional collaborations to monetize various other assets," he added.

For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.

You May Also Be Interested In

• MFA Financial (MFA) Misses Q3 EPS by 2c
• Rigel to present R289 and Tavalisse data at ASH meeting
• Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology Annual Meeting and Exposition